Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07867925 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Predicting Endocrine Resistance Using Molecular Imaging and Liquid Biopsy in Metastatic Breast Cancer

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This prospective observational study aims to evaluate the prognostic value of molecular imaging biomarkers derived from baseline \[18F\]FES and \[18F\]FDG PET/CT for progression-free survival in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer receiving first-line endocrine therapy combined with a CDK4/6 inhibitor. In a subset of patients with available tumor tissue, paired tumor tissue next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis will also be performed to investigate their associations with imaging biomarkers, treatment response, and clinical outcomes.
Trial Details
NCT Number NCT07867925
Lead Sponsor Asan Medical Center
Conditions
(from sponsor)		 Metastatic Breast Cancer (HR+/ HER2-)
Related terms Breast Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov